We urgently need more answers for the patients affected by mesothelioma, a devastating diasese whose prognosis is 6-9 months from the diagnosis. We are now living the era of plateau of the epidemiology due to industrial use of amiantus of the last century.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Pleura - Mesothelioma
September 20, 2017
March 24, 2017
Paul Van Schil of Antwerp University Hospital, Antwerp, Belgium argues that surgery offers the best outcome for patients with mesothelioma.
March 16, 2017
Robert Rintoul of Papworth Hospital, Cambridge, UK, reviews the outcomes of major mesothelioma trials, and argues that all mesothelioma surgery is currently palliative.
September 27, 2016
Semiautomated CT volumetric measurements of tumor volume in patients with malignant pleural mesothelioma were compared to stage and overall survival. CT volumes correlated well with stage and survival.
September 4, 2015
This study used a multicenter cohort in Italy to identify prognostic indicators for 3-year survival in patients who had undergone extrapleural pneumonectomy (EPP) for mesothelioma. 23% lived 3 years or longer. This survival was related to age, epitheliod histology, lack of asbestos exposure, and involved LN ratio. A risk score for survival was dev
July 30, 2015
The ESMO Guidelines Committee provides an update to its guidelines for evaluation and management of malignant pleural mesothelioma. They recommend against screening. A biopsy demonstrating tissue invasion is required for a definitive diagnosis. Definitions for different extents of surgical radicality are provided. No specific recommendations for
April 30, 2015
This prospective study evaluated QOL and lung function after extended pleurectomy/decortication (EPD) for mesothelioma in 36 patients. Patients with performance status (PS) 0 experienced little or no improvement in QOL but did have a significant decrease in lung function (FVC, FEV1, TLC, DLCO). Patients with PS 1-2 experienced improved QOL and no i
September 25, 2014
This randomized controlled trial compared VATS partial pleurectomy (VAT-PP) to talc pleurodesis in patients with malignant mesothelioma and a pleural effusion, evaluating overall survival. VAT-PP was associated with significantly greater surgical complications, a higher rate of respiratory complications and prolonged air leak, and a significantly lo
September 16, 2014
This retrospective review of pts undergoing complete resection by extrapleural pneumonectomy 1998-2011 for malignant mesothelioma focused on stage predictors of survival. Surgical mortality was 5%. Overall survival at 5 years was 14%, and median survival was 18 mos. Median survival for N1 or N2 disease was 17 and 13 mos, respectively. Nodal stag
August 11, 2014
Data from 6 cohort studies were evaluated to assess the ongoing risk of mesothelioma more than 40 years after initial environmental exposure to asbestos. Among over 22,000 of those exposed, 707 cases of pleural mesothelioma were diagnosed. The rate and risk increased until 45 years after exposure, then the rate of increase tapered off somewhat.